CD8 is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CD8 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

CD8 is an inclusion criterion in 1 clinical trial for adult T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CD8 status and adult T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

CD8 is an inclusion criterion in 1 clinical trial for aggressive NK-cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains CD8 status and aggressive NK-cell leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

CD8 is an inclusion criterion in 1 clinical trial for angioimmunoblastic T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD8 status and angioimmunoblastic T-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CD8 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD8 status and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CD8 is an inclusion criterion in 1 clinical trial for cutaneous lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD8 status and cutaneous lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CD8 is an inclusion criterion in 1 clinical trial for enteropathy-associated T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD8 status and enteropathy-associated T-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CD8 is an inclusion criterion in 1 clinical trial for follicular T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD8 status and follicular T-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CD8 is an inclusion criterion in 1 clinical trial for hepatosplenic T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD8 status and hepatosplenic T-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CD8 is an inclusion criterion in 1 clinical trial for monomorphic epitheliotropic intestinal T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD8 status and monomorphic epitheliotropic intestinal T-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CD8 is an inclusion criterion in 1 clinical trial for nasal type extranodal NK/T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD8 status and nasal type extranodal NK/T-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CD8 is an inclusion criterion in 1 clinical trial for nodal peripheral T-cell lymphoma with TFH phenotype, of which 1 is open and 0 are closed. Of the trial that contains CD8 status and nodal peripheral T-cell lymphoma with TFH phenotype as inclusion criteria, 1 is phase 1 (1 open) [4].

CD8 is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD8 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CD8 is an inclusion criterion in 1 clinical trial for primary cutaneous anaplastic large cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD8 status and primary cutaneous anaplastic large cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CD8 is an inclusion criterion in 1 clinical trial for primary cutaneous gamma-delta T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD8 status and primary cutaneous gamma-delta T-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CD8 is an inclusion criterion in 1 clinical trial for primary cutaneous T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD8 status and primary cutaneous T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CD8 is an inclusion criterion in 1 clinical trial for subcutaneous panniculitis-like T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD8 status and subcutaneous panniculitis-like T-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CD8 is an inclusion criterion in 1 clinical trial for systemic anaplastic large cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD8 status and systemic anaplastic large cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CD8 is an inclusion criterion in 1 clinical trial for T-cell large granular lymphocyte leukemia, of which 1 is open and 0 are closed. Of the trial that contains CD8 status and T-cell large granular lymphocyte leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

CD8 is an inclusion criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CD8 status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].